2008
DOI: 10.1016/s0140-6736(08)61555-x
|View full text |Cite
|
Sign up to set email alerts
|

Pompe's disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

7
518
0
36

Year Published

2012
2012
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 638 publications
(561 citation statements)
references
References 126 publications
7
518
0
36
Order By: Relevance
“…The HHS Secretary's Advisory Committee on Heritable Disorders in Newborns and Children is tasked with overseeing the process 5 of adding emerging conditions 6,7 to the recommended panel. The most recent additions are acid α-glucosidase (GAA) deficiency (Pompe disease), 8 α-L-iduronidase (IDUA) deficiency (MPS I), 9 and X-linked adrenoleukodystrophy. 10 Other lysosomal disorders, particularly galactocerebrosidase (GALC) deficiency (Krabbe disease), 11 have been turned down by the committee because they lacked evidence of net benefits.…”
Section: Introductionmentioning
confidence: 99%
“…The HHS Secretary's Advisory Committee on Heritable Disorders in Newborns and Children is tasked with overseeing the process 5 of adding emerging conditions 6,7 to the recommended panel. The most recent additions are acid α-glucosidase (GAA) deficiency (Pompe disease), 8 α-L-iduronidase (IDUA) deficiency (MPS I), 9 and X-linked adrenoleukodystrophy. 10 Other lysosomal disorders, particularly galactocerebrosidase (GALC) deficiency (Krabbe disease), 11 have been turned down by the committee because they lacked evidence of net benefits.…”
Section: Introductionmentioning
confidence: 99%
“…The most severe and rapidly progressive infantile form is fatal within the first months of life; in milder childhood, juvenile, and adult forms cardiac muscle is usually spared, but slowly progressive muscle disease eventually leads to respiratory insufficiency and a shortened life expectancy. 22 Current treatment with enzyme replacement therapy (ERT) is very effective in restoring cardiac function and extending the life span of infants, but it fails to significantly reverse or halt the progression of the disease in skeletal muscle. [23][24][25] We have previously shown in the Gaa-KO mouse model that in addition to the enlargement of glycogen-loaded lysosomes, abnormal autophagy, accumulation of autophagic substrates, and impaired autophagosomal-lysosomal fusion greatly contribute to the pathogenesis of muscle damage and to muscle resistance to ERT.…”
Section: Introductionmentioning
confidence: 99%
“…Glycogen-storage disease type 2 (Pompe disease) may present prominent clinical resemblance to limb girdle muscular dystrophy, with predominant proximal weakness and autosomal recessive inheritance 18 . Some peculiar clinical characteristics may suggest Pompe disease diagnosis such as respiratory insufficiency and increased tongue volume 18 .…”
Section: How Do We Know If Our Patients Have a Limb Girdle Muscular Dmentioning
confidence: 99%
“…Some peculiar clinical characteristics may suggest Pompe disease diagnosis such as respiratory insufficiency and increased tongue volume 18 . Sometimes, respiratory insufficiency may manifest exclusively as increased susceptibility to respiratory infections, matinal headache, and daily somnolence, due to nocturnal hypoxia 19 .…”
Section: How Do We Know If Our Patients Have a Limb Girdle Muscular Dmentioning
confidence: 99%